ReviewRecent advances in drug delivery and formulation2025
Unlocking Dendrimers Future Potential for Brain-Specific Drug Delivery in Cerebroanoreach.
Review in Recent advances in drug delivery and formulation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Intranasal Biodegradable Nanomedicine for Epilepsy Management: Targeting the Brain Beyond the Blood-Brain Barrier.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Blood-Brain Barrier (BBB) makes it extremely difficult to get drugs to the brain, yet highly branching macromolecules known as dendrimers show a lot of promise in this regard. This review delves into the current and future prospects of dendrimers in facilitating brain-specific drug delivery within the framework of cerebroanoreach. The unique structural features of dendrimers allow for precise regulation of surface function, size, and shape, which are critical for targeting specific cell types in the brain and increasing blood-brain barrier permeability. Second, they can be conjugated with imaging agents, peptides, or pharmaceuticals thanks to their versatile surface chemistry, which enhances diagnostic capabilities and treatment efficacy. Recent advances in nanoformulations based on dendrimers have demonstrated promising improvements in the solubility, stability, and bioavailability of medications, suggesting their possible use in therapeutic contexts. Various obstacles, such as toxicity profiles and production bottlenecks that require scaling up are also addressed, with a focus on ongoing research projects and potential remedies. One potential solution to the problems with cerebroanoreach is the use of dendrimers for brain-specific drug delivery; this could revolutionize the treatment of neurological diseases and the precision of neurology diagnostics. By synthesizing current knowledge and future directions, this review urges the continuance of interdisciplinary collaboration, which is crucial for fully realizing the potential of dendrimers in neuroscience and therapeutic innovation.
Indexed as
Identifiers
40495598What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.